Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors

Expression and prognostic value

Rosager, Ann Mari; Sørensen, Mia D; Dahlrot, Rikke H; Hansen, Steinbjørn; Schonberg, David L; Rich, Jeremy N; Lathia, Justin D; Kristensen, Bjarne W

Published in:
PLOS ONE

DOI:
10.1371/journal.pone.0182954

Publication date:
2017

Document version:
Final published version

Document license:
CC BY

Citation for published version (APA):
Rosager, A. M., Sørensen, M. D., Dahlrot, R. H., Hansen, S., Schonberg, D. L., Rich, J. N., Lathia, J. D., & Kristensen, B. W. (2017). Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLOS ONE, 12(8), [e0182954]. https://doi.org/10.1371/journal.pone.0182954
Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value

Ann Mari Rosager¹,², Mia D. Sørensen¹,²*, Rikke H. Dahlrot³, Steinbjørn Hansen²,³, David L. Schonberg⁴, Jeremy N. Rich⁴, Justin D. Lathia⁵, Bjarne W. Kristensen¹,²

¹ Department of Pathology, Odense University Hospital, Odense, Denmark, ² Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ³ Department of Oncology, Odense University Hospital, Odense, Denmark, ⁴ Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, United States of America, ⁵ Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, United States of America

* mia.soerensen@rsyd.dk

Abstract

Astrocytic brain tumors are the most frequent primary brain tumors. Treatment with radio- and chemotherapy has increased survival making prognostic biomarkers increasingly important. The aim of the present study was to investigate the expression and prognostic value of transferrin receptor-1 (TfR1) as well as ferritin heavy (FTH) and light (FTL) chain in astrocytic brain tumors. A cohort of 111 astrocytic brain tumors (grade II-IV) was stained immunohistochemically with antibodies against TfR1, FTH, and FTL and scored semi-quantitatively. Double-immunofluorescence stainings were established to determine the phenotype of cells expressing these markers. We found that TfR1, FTH, and FTL were expressed by tumor cells in all grades. TfR1 increased with grade (p < 0.001), but was not associated with prognosis in the individual grades. FTH and FTL were expressed by tumor cells and cells with microglial/macrophage morphology. Neither FTH nor FTL increased with malignancy grade, but low FTH expression by both tumor cells (p = 0.03) and microglia/macrophages (p = 0.01) correlated with shorter survival in patients anaplastic astrocytoma. FTL-positive microglia/macrophages were frequent in glioblastomas, and high FTL levels correlated with shorter survival in the whole cohort (p = 0.01) and in patients with anaplastic astrocytoma (p = 0.02). Double-immunofluorescence showed that TfR1, FTH, and FTL were co-expressed to a limited extent with the stem cell-related marker CD133. FTH and FTL were also co-expressed by IBA-1-positive microglia/macrophages. In conclusion, TfR1 was highly expressed in glioblastomas and associated with shorter survival in the whole cohort, but not in the individual malignancy grades. Low levels of FTH-positive tumor cells and microglia/macrophages were associated with poor survival in anaplastic astrocytomas, while high amounts of FTL-positive microglia/macrophages had a negative prognostic value. The results suggest that regulation of the iron metabolism in astrocytic brain tumors is complex involving both autocrine and paracrine signaling.
Introduction

Astrocytic brain tumors are the most frequent and aggressive brain tumors in adults [1]. The most common and aggressive type is the glioblastoma (GBM) having a median survival of 15 months [2, 3]. High-dose radiotherapy and temozolomide have increased survival [2, 3] making prognostic biomarkers in gliomas increasingly important. Tumor cells in GBM display a cellular hierarchy with brain tumor-initiating cells (BTIC) at the apex [4, 5]. BTIC are located in niches and thrive in stressful conditions such as hypoxia, inflammation, oxidative stress, and low supply of glucose [6–10]. Iron metabolism is thought to be involved in mechanisms supporting these conditions [11–13]. Deregulation of the iron homeostasis has also been linked to other cancers as well as neuro-degenerative diseases [14].

Iron is an important co-factor required for biological activity of many enzymes, and the iron metabolism is strictly controlled to avoid free iron toxicity [15]. Iron enters the brain across the blood-brain-barrier, and uptake in the capillary endothelial cells is regulated by transferrin receptor-1 (TfR1) [16]. A similar regulation has been reported in cancer cells [17]. Intracellular iron is stored by two subtypes of the protein ferritin that differ in their subunits, either ferritin heavy (FTH) or light (FTL) chain [18]. FTH is important for rapid uptake and reutilization of iron, while FTL is associated with long-term storage [19].

High expression of TfR1 has been observed in different cancers including breast, lung, and bladder cancer as well as in malignant gliomas [17]. In The Cancer Genome Atlas (TCGA) dataset, a negative correlation was found between overall survival and high mRNA levels of TfR1, FTL, and FTH in gliomas. Recently, similar results were obtained when the three iron-related proteins were investigated on tissue microarrays (TMAs) containing tissue from 95 gliomas of oligodendroglial and astrocytic subtype [20]. Supporting BTIC functions, TfR1-positive GBM cells formed tumorspheres more frequently than TfR1-negative cells in vitro. Moreover, in vivo xenografting showed that mice implanted with TfR1-high GBM cells developed tumors earlier than mice implanted with TfR1-low GBM cells [20]. BTICs sorted based on the expression of CD133 showed elevated levels of TfR1, FTH, and FTL compared to non-BTICs. When short hairpin RNA interference was used to ablate ferritin activity, decreased BTIC proliferation was observed. Further, implanting BTICs in mice containing FTH or FTL knockdown resulted in sparse or absent tumor formation [20].

The aim of the present study was to investigate the expression and prognostic value of TfR1, FTL, and FTH in a patient cohort of 111 astrocytomas. Immunohistochemical staining was performed on whole slides as expression of BTIC-related markers may be under- or over-estimated in TMAs due to the heterogeneity of gliomas [21]. Also, a possible expression of FTL and FTH by microglia/macrophages could be taken more comprehensively into account. In addition, we wanted to investigate the prognostic potential of TfR1, FTL, and FTH in individual glioma grades, since this aspect is of high clinical interest. To determine the phenotype of TfR1-, FTL-, and FTH-positive cells, a panel of double-immunofluorescence stainings was established consisting of the BTIC-related markers CD133 [22, 23] and nestin [24–26], the astrocytic marker glial fibrillary acidic protein (GFAP), and the microglial/macrophage marker ionized calcium-binding adapter molecule 1 (IBA-1).

Material and methods

Odense University Hospital (OUH) astrocytoma cohort

The tumor tissue samples (n = 111) were obtained from patients diagnosed with primary astrocytoma and included 70 GBMs (World Health Organization (WHO) grade IV), 18 anaplastic astrocytomas (AAs) (WHO grade III), and 23 diffuse astrocytomas (DAs) (WHO grade...
II). All patients underwent initial surgery between 1994 and 2005 at OUH, Denmark. None of the patients received treatment prior to the surgery. To ensure a sufficient and representative amount of high quality viable tumor tissue, we excluded: tumor tissue removed by ultrasonic aspiration, gliomas where all the material had been frozen before paraffin embedding, and biopsies where the material measured less than 4 mm. The tumors were re-evaluated by two independent neuropathologists according to the WHO guidelines 2007 [27]. Patient characteristics are presented in Table 1.

**Tissue**

Fresh tissue biopsies were fixed in 4% neutral buffered formaldehyde and paraffin embedded. Three μm sections were cut on a microtome and stained routinely with haematoxylin-eosin to define representative tumor regions.

Normal brain tissue specimens for staining controls were obtained from two adult autopsies. Cause of death was not related to any CNS diseases. The tissue was fixed in 4% neutral buffered formaldehyde for 24 hours.

The official Danish ethical review board named the Regional Scientific Ethical Committee of the Region of Southern Denmark approved the use of human glioma tissue (permission J. No. S-2011 0022). Use of the tissue was not prohibited by any of the patients according to the Danish Tissue Application Register.

**Immunohistochemistry**

Three μm paraffin sections were stained on a Dako Autostainer Universal Staining System (Dako, Glostrup, Denmark). The sections were deparaffinized, and heat induced epitope retrieval (HIER) was performed by incubation in a buffer solution consisting of 10 mmol/L Tris-base and 0.5 mmol/L EGTA, pH 9. After blocking of endogenous peroxidase activity by incubation in 1.5% hydrogen peroxide, the sections were incubated for 60 min with primary antibodies against TfR1 (CD71) (10F11, 1+50, NovoCastra, Newcastle, United Kingdom), FTH (ab65080, 1+800, Abcam, Cambridge, United Kingdom), or FTL (ab69090, 1+1000, Abcam). The antigen-antibody complex was detected using EnVision (Dako). Visualization was performed using DAB (diaminobenzidine) as chromogen. Finally, sections were counterstained with Mayer’s hematoxylin, and coverslips were mounted with Aquatex. Paraffin sections from a TMA containing 28 normal tissues and 12 cancers were used as controls. Omitting primary antibodies served as negative controls as well as controls for non-specific staining related to the detection system.

| Table 1. Clinicopathological characteristics of patient samples. |
|-----------------|-----|-----|-----|-----|
| All astrocytomas | DA  | AA  | GBM |
| Patients (n)     | 111 | 23  | 18  | 70  |
| OS (months)      | 10.5| 55.5| 18.4| 8.4 |
| Range (0.07–241.3) | (2.1–241.3) | (2.2–110.1) | (0.07–153.4) |
| Age (years)      | 58  | 45  | 57  | 61  |
| Range (2–78)     | (2–75) | (14–77) | (21–78) |
| Sex (male/female)| 70/41| 15/8| 11/7| 44/26|
| Endpoint (alive/dead) | 6/105| 5/18| 0/18| 1/69|

**Abbreviations:** AA anaplastic astrocytoma, DA diffuse astrocytoma, GBM glioblastoma, OS overall survival.

https://doi.org/10.1371/journal.pone.0182954.t001
Double-immunofluorescence

Double-immunofluorescence stainings were performed on a TMA containing tissue from nine GBMs, normal colon, placenta, cerebellum, and rat hippocampus as previously described [20, 28, 29]. The preparations as well as the first step in the stainings were as described above. After detection of TfR1 (CD71) (1+200), FTH (1+12000), or FTL (1+16000) using Catalyzed Signal Amplification II kit with FITC (CSA II, Dako), a second round of HIER followed by quenching of endogenous peroxidase was performed. Sections were then incubated with antibodies against nestin (96908, 1+200, R&D systems, Minneapolis, Minnesota, USA), CD133 (W63B3C1, 1+40, Miltenyi Biotec, Teterow, Germany), GFAP (Z0334, 1+8000, Dako), or IBA-1 (019–19741 1+12000, Wako Pure Chemical Industries, Osaka, Japan). Tyramide Amplification Signal Cyanine 5 (TSA-Cy5, Perkin Elmer, Waltham, Massachusetts, USA) was used as detection system. Sections were mounted with VECTASHIELD Antifade Mounting Medium with 4.6-diamidino-2-phenylindole (DAPI, VWR International, Radnor, Pennsylvania, USA). Fluorescent images were taken with a Leica DM6000B microscope connected to an Olympus DP72 1.4 Mega Pixel CCD (Olympus, Tokyo, Japan) camera using DAPI (Omega XF06, Omega Optical, Brattleboro, Vermont, USA), FITC (Leica, Wetzlar, Germany) and Cy5 (Omega XF110-2) filters.

Pathological scoring

The immunohistochemical stainings were assessed using semi-quantitative scoring on whole slides. Prior to scoring of the whole cohort, ten tumors were evaluated and scored repeatedly to ensure reproducibility. Before the scoring was performed, a set of criteria was established and carefully followed (Table 2). For each individual staining, two parameters, “tumor cell fraction” and “tumor cell intensity”, were assessed and given a score from 0–2 with 0 indicating negative staining, 1 moderate staining, and 2 strong staining. The parameter “tumor cell score” was defined as a sum of the tumor cell fraction score and tumor cell intensity score with a maximum score of 4. In the ferritin stainings, positive cells with microglial/macrophage

| Table 2. Pathological scoring of TfR1, FTH, and FTL. |
|-----------------|-----|-----|-----|
| **TfR1 score**  | 0   | 1   | 2   |
| Positive tumor cell fraction | 0% to <2% | 2% to < 75% | 75% to 100% |
| Tumor cell intensity | None | Faint | Intense |
| **FTH score** | 0   | 1   | 2   |
| Positive tumor cell fraction | 0% to <2% | 2% to < 75% | 75% to 100% |
| Tumor cell intensity | None | Faint | Intense |
| Positive microglial fraction | 0% to <2% | 2% to < 75% | 75% to 100% |
| Microglial intensity | None | Faint | Intense |
| **FTL score**  | 0   | 1   | 2   |
| Positive tumor cell fraction | 0% to <2% | 2% to < 75% | 75% to 100% |
| Tumor cell intensity | None | Faint | Intense |
| Positive microglial fraction | 0% to <2% | 2% to < 75% | 75% to 100% |
| Microglial intensity | None | Faint | Intense |

For each tumor, a tumor cell score for TfR1, FTH, and FTL was calculated by adding up the two tumor scores: positive tumor cell fraction and tumor cell intensity, resulting in a maximum score of 4. Similarly, a microglial score for FTH and FTL was calculated by adding up the two microglial scores: positive microglial fraction and microglial intensity resulting in a maximum score of 4.

Abbreviations: FTH ferritin heavy chain, FTL ferritin light chain, TfR1 transferrin receptor-1.

https://doi.org/10.1371/journal.pone.0182954.t002
morphology were observed, and two additional parameters were therefore scored: “microglial fraction” and “microglial intensity”. The parameter “microglial score” was defined as a sum of the microglial fraction score and microglial intensity score with a maximum score of 4. Cells with microglial/macrophage morphology were not incorporated into the tumor cell scores. Necrotic areas and infiltration zones were not included in the assessment. Patient data are available in S1 File.

**In silico analyses of the Cancer Genome Atlas (TCGA)**

TCGA gene expression datasets for Tfr1 (TFRC), FTH (FTH1), FTL, and IBA-1 (AIF-1) were exported from GlioVis (https://gliovis.bioinfo.cnio.es). Data were available for 497 patients with primary GBM [30]. Datasets used in the present study are available in S2 File.

**Statistical analysis**

Tumor cell score and microglial score were compared with tumor grades using the non-parametric Kruskal Wallis test followed by Dunn’s multiple comparisons test. Overall survival was defined as time from primary surgery until death or date of censoring (April 10th, 2015). The univariate relationships were illustrated by Kaplan-Meier plots, and differences in overall survival were analyzed using Log Rank tests. This was performed for all WHO grades combined and for DAs, AAs, and GBMs separately. Multivariate Cox proportional hazard regression analyses including age and sex were performed for GBMs. For survival analyses, patients were grouped into two, based on the summed scores with score 0–2 representing the low expression group and score 3–4 representing the high expression group. All assumptions were tested, and all analyses were carried out in STATA (StataCorp LP, Bryan, Texas, USA).

Correlations between IBA-1 gene expression, GBM subtypes, and expression of the three iron-related genes were investigated using the non-parametric Spearman’s correlation. Using the Tfr1, FTH, and FTL datasets, survival analyses were carried out for each GBM subtype with the median as cutoff value.

**Results**

**Staining in normal brain**

In the subventricular zone Tfr1-positive cells were observed in the ependymal layer (Fig 1A), while few cells in and beneath the ependymal layer were FTH-positive (Fig 1B). The ependymal cells did not express FTL, but a few cells beneath the ependymal expressed FTL (Fig 1C). For Tfr1, neurons in the neocortex had a weak expression (Fig 1D), and endothelium was mainly positive stained in the small capillaries. For FTH, neurons in neocortex showed a moderate expression, and the neuropil had a weak staining, while some cells morphologically resembling microglia had a stronger staining (Fig 1E). A similar staining pattern was found for FTL (Fig 1F).

**Tumor cell staining in astrocytomas**

In most DAs, Tfr1 was not present (Fig 1G), while FTH and FTL expression patterns were heterogeneous with strong, diffuse expression in some tumors and weak expression in others (Fig 1H and Fig 1I). Likewise most AAs were Tfr1-negative, but some expressed the protein (Fig 2A), and FTH and FTL was heterogeneously expressed (Fig 2B and Fig 2C). GBM cells were positive for Tfr1 with a heterogeneous expression pattern containing regions of high intensity with multiple positive tumor cells as well as regions without any Tfr1-expressing
Multinucleated giant cells showed a weak TfR1 expression (Fig 2D), but had an intense expression of FTH and especially FTL (Fig 2E and Fig 2F). TfR1-positive tumor cells were often seen near blood vessels (Fig 2G), and in all tumors, the endothelium of small blood vessels expressed TfR1 thereby serving as an internal positive control. In contrast, blood vessels including glomeruloid vessels lacked expression of FTH (Fig 2H) and FTL (Fig 2I). Cells surrounding pseudo-palisading necrosis expressed TfR1 (Fig 2J), FTH (Fig 2K) as well as FTL (Fig 2L).

In general, the expression patterns of FTH and FTL appeared very similar, although more cells were positive for FTL, and the intensity of the positive cells was often stronger than that of FTH-positive cells. The cells with the strongest FTL and FTH intensities resembled microglia/macrophages exhibiting microstellate or macrophage morphology.

**Fig 1.** Normal brain tissue from subventricular zone and neocortex as well as DAs immunohistochemically stained with TfR1, FTH, and FTL. Cells in the ependymal layer expressed TfR1 (A) and FTH (B). No expression of FTL (C) in the ependymal layer was seen. A few cells beneath the ependymal layer were positive for FTH (B) and FTL (C) (arrows). In the neocortex, there was a weak TfR1 neuronal staining (D), but a stronger neuronal staining for FTH (E) and FTL (F), which also stained the neuropil. In DAs, TfR1 was mainly expressed by the endothelium (arrow) (G). The FTH (H) and FTL (I) stainings were pronounced in many DAs with staining of both tumor cells (arrows) and microglia (arrowheads). **Abbreviations:** DA diffuse astrocytoma, FTH ferritin heavy chain, FTL ferritin light chain, TfR1 transferrin receptor-1. Scale bar: 100 μm.

https://doi.org/10.1371/journal.pone.0182954.g001
Association with grade and prognostic impact of tumor cell score in astrocytomas

The TfR1 tumor cell score increased with malignancy grade (p < 0.001) (Fig 3A). Neither FTH (Fig 3B) nor FTL (Fig 3C) increased with grade.

When combining all grades, high TfR1 tumor cell score was associated with a poor prognosis (HR 2.5; 95% CI 1.59–3.79; p < 0.001) (score 0–2: n = 74 and score 3–4: n = 39) (Fig 3D). Differences in overall survival based on TfR1 expression could not be compared in DAs, since all DAs received a low tumor cell score (Fig 3G). TfR1 tumor cell score was not associated with overall survival in AAs (HR 1.2; 95% CI 0.27–5.69; p = 0.78) (score 0–2: n = 15 and score

---

**Fig 2.** AAs and GBMs immunohistochemically stained with TfR1, FTH, and FTL. AAs showed weak TfR1 staining (A) and stronger FTH (B) and FTL (C) staining. GBMs with giant cells were weakly positive for TfR1 (D), moderately positive for FTH (E), and strongly positive for FTL (F). GBMs had no or limited glomeruloid staining for TfR1 (G), FTH (H), or FTL (I) (arrows). In GBMs with pseudo-palisading necroses (asterisks) TfR1-positive (J), FTH-positive (K), and FTL-positive (L) cells were observed in perinecrotic areas. Cells with microglial/macrophage morphology were easily identified in both the FTH (arrowheads) (E and K) and FTL stainings (arrowheads) (C and L). *Abbreviations:* AA anaplastic astrocytoma, FTH ferritin heavy chain, FTL ferritin light chain, GBM glioblastoma, TfR1 transferrin receptor-1. Scale bar: (A-I) 100 μm, (J-L) 100 μm.
Iron-related proteins in astrocytomas

A. TfR1

B. FTH

C. FTL

D. All astrocytomas

E. All astrocytomas

F. All astrocytomas

G. DA

H. DA

I. DA

J. AA

K. AA

L. AA

M. GBM

N. GBM

O. GBM

Overall survival (%)

Months

Score

0-2

3-4

HR 2.5

p=0.001

HR 0.6

p=0.01

HR 1.0

p=0.91

HR 1.1

p=0.85

HR 0.7

p=0.55

HR 0.97

p=0.91

HR 1.4

p=0.19
Combining all astrocytomas, high FTH tumor cell score was associated with better outcome (HR 0.6; 95% CI 0.37–0.87; p = 0.01) (score 0–2: n = 35 and score 3–4: n = 76) (Fig 3E). Only one DA had a low FTH tumor cell score preventing statistical comparison (Fig 3H). In AAs, a high FTH tumor cell score was associated with better outcome (HR 0.3; 95% CI 0.09–0.90; p = 0.03) (score 0–2: n = 7 and score 3–4: n = 11) (Fig 3K). No association with overall survival was observed in GBMs neither in univariate (HR 0.97; 95% CI: 0.60–1.59; p = 0.91) (score 0–2: n = 35 and score 3–4: n = 37) (Fig 3N) nor in multivariate analysis (Table 3).

FTL tumor cell score was not associated with overall survival in all astrocytomas combined (HR 1.0; 95% CI 0.67–1.56; p = 0.91) (score 0–2: n = 31 and score 3–4: n = 81) (Fig 3F), in DAs (HR 1.1; 95% CI 0.39–3.12; p = 0.85) (score 0–2: n = 6 and score 3–4: n = 17) (Fig 3I), or in AAs (HR 0.7; 95% CI 0.22–2.25; p = 0.55) (score 0–2: n = 4 and score 3–4: n = 14) (Fig 3L). In GBMs, FTL did not correlate with survival, however, the subgroup of patients with low FTL tumor cell score tended to have a better prognosis (HR 1.4; 95% CI 0.84–2.43; p = 0.19) (score 0–2: n = 21 and score 3–4: n = 49) (Fig 3O); but FTL did not have an independent prognostic value in GBMs (Table 3).

### Table 3. Multivariate analysis for patients with GBMs (n = 70) with TfR1, FTH, and FTL tumor cell score.

| Variable | TfR1 HR (95% CI) | p-value | FTH HR (95% CI) | p-value | FTL HR (95% CI) | p-value |
|----------|-----------------|---------|-----------------|---------|-----------------|---------|
| Age      | 1.0 (0.99–1.04) | 0.39    | 1.0 (0.98–1.03) | 0.60    | 1.0 (0.98–1.03) | 0.62    |
| Gender   |                 |         |                 |         |                 |         |
| Female   | 1.0             |         | 1.0             |         | 1.0             |         |
| Male     | 1.1 (0.66–1.82) | 0.72    | 1.1 (0.66–1.82) | 0.83    | 1.8 (1.09–2.99) | 0.02    |
| TCS      |                 |         |                 |         |                 |         |
| 0–2      | 1.0             |         | 1.0             |         | 1.0             |         |
| 3–4      | 1.1 (0.70–1.84) | 0.62    | 0.9 (0.54–1.59) | 0.78    | 1.5 (0.90–2.66) | 0.12    |

**Abbreviations:** CI confidence interval, FTH ferritin heavy chain, FTL ferritin light chain, HR hazard ratio, TCS tumor cell score, TfR1 transferrin receptor-1.

https://doi.org/10.1371/journal.pone.0182954.t003
microglial score was associated with a better overall survival (HR 0.2; 95% CI 0.04–0.64; p = 0.01) (score 0–2: n = 7 and score 3–4: n = 11) (Fig 4G), while no association with overall survival was observed for patients with GBM in either in the univariate (HR 1.3; 95% CI 0.82–2.18; p = 0.24) (score 0–2: n = 31 and score 3–4: n = 39) (Fig 4I) or multivariate analyses (Table 4).

Low FTL microglial score was associated with a better overall survival in all astrocytomas combined (HR 1.8; 95% CI 1.56–2.79; p = 0.01) (Fig 4D) (score 0–2: n = 33 and score 3–4: n = 79), and a similar trend was observed in DAs (HR 2.3; 95% CI 0.88–6.81; p = 0.09) (score 0–2: n = 11 and score 3–4: n = 12) (Fig 4F). In AAs, low FTL microglial score was associated with better outcome (HR 4.9; 95% CI 1.31–17.95; p = 0.02) (Fig 4H) (score 0–2: n = 6 and score 3–4: n = 12), while no association was found in GBMs (HR 0.7; 95% CI 0.37–1.16; p = 0.15) (score 0–2: n = 16 and score 3–4: n = 54) (Fig 4J). Multivariate analysis of GBMs did not provide any additional information (Table 4).

Double-immunofluorescence

TfR1 was expressed by CD133-positive tumor cells (Fig 5A–5D) and to a limited degree by nestin-positive tumor cells (Fig 5E–5H). Tumor cells that co-expressed TfR1 and GFAP were also identified (Fig 5I–5L). The two ferritin stainings showed similar co-expression patterns. Few FTH-positive tumor cells co-expressed CD133 (Fig 6A–6D), while no co-expression between FTH and nestin was observed (Fig 6E–6H). Some IBA-1-positive cells co-expressed FTH (Fig 6I–6L). A similar co-expression pattern was observed for FTL (Fig 7A–7L).

In silico analyses

To investigate the relation between the iron-related molecules and microglia/macrophages further, correlation analyses between IBA-1 and TfR1, FTH, and FTL were performed using the TCGA dataset. No significant correlation was found between IBA-1 and TfR1 mRNA expression (rs = -0.05; 95% CI 0.14–0.04; p = 0.24) (Fig 8A), while IBA-1 was positively correlated.
with both FTH ($r_s = 0.41; 95\% \text{ CI } 0.34–0.49; p < 0.001$) (Fig 8B) and FTL ($r_s = 0.67; 95\% \text{ CI } 0.61–0.71; p < 0.001$) (Fig 8C).

Investigating the mRNA expression levels of TfR1, FTH, and FTL in the four different GBM subtypes, TfR1 levels were found to be significantly lowest in the proneural subtype compared to the classical, mesenchymal, and neural subtypes ($p < 0.001$) (Fig 8D). FTH expression was significantly higher in the mesenchymal and neural subtype compared to the classical ($p < 0.001$) and proneural subtypes ($p < 0.001$ and $p < 0.01$, respectively) (Fig 8E), while FTL expression levels were highest in the mesenchymal subtype ($p < 0.001$ or $p < 0.01$) (Fig 8F).

Investigating the association between iron-related mRNA levels and survival in the different GBM subtypes showed that TfR1, FTH, and FTL had limited prognostic value in classical GBMs ($p > 0.05$) (S1A–S1C Fig). In mesenchymal GBMs, only high levels of TfR1 negatively correlated with overall survival (HR 1.4; 95\% CI 1.00–2.01; $p = 0.049$) (S1D–S1F Fig). In neural GBMs, overall survival was not associated with TfR1, FTH, or FTL ($p > 0.05$) (S1G–S1I Fig). In proneural GBMs, high levels of TfR1 were significantly associated with shorter overall survival (HR 2.3; 95\% CI 1.49–3.39; $p < 0.001$) (S1J Fig); while FTH and FTL did not correlate with survival ($p > 0.05$) (S1K and S1L Fig).

**Discussion**

In our cohort, TfR1 expression was predominantly seen in GBMs, and high TfR1 expression was associated with worse prognosis analyzing all astrocytic brain tumors together. High TfR1

Fig 5. **TfR1 double-immunofluorescence stainings.** Co-expression of TfR1 and CD133 was observed in a number of tumor cells (A–D). Some tumor cells showed limited co-expression with nestin (E–H). A few tumor cells expressed both TfR1 and GFAP (I–L). **Abbreviations:** GFAP glial fibrillary acidic protein, TfR1 transferrin receptor-1. Scale bar: 50 μm.

https://doi.org/10.1371/journal.pone.0182954.g005
expression has also been observed in other cancers [31–34]. Recently, analysis of brain tumor data sets from Oncomine suggested that high mRNA levels of TfR1 were associated with high tumor grade. Analyzing the TCGA and the National Cancer Institute REpository for Molecular BRAin Neoplastic Data (NCI REMBRANDT) datasets, high TfR1 levels were found correlate with shorter overall survival in patients with glioma, and similar results were found when investigating protein expression data from grade II-IV TMAs [20]. In the present study, we performed a more comprehensive analysis and found no association between TfR1 expression and survival in the individual astrocytoma grades. This suggests that the prognostic significance of the iron-related proteins previously observed in all astrocytomas is related to WHO grade and does not provide additional prognostic information. We found that cells with tumor morphology co-expressed TfR1 and GFAP; additionally we observed co-expression of TfR1 and the stem cell-related markers CD133 and nestin, which is consistent with recently reported data demonstrating that GBM cells co-express TfR1 and the stem cell-related marker SOX2 [20]. Overall, these findings suggest that TfR1 may play a role at different levels of the tumor cell differentiation hierarchy; however, the association between TfR1 and cellular differentiation needs further investigation.

Almost all astrocytic tumors in our cohort expressed the two ferritin proteins. High FTH tumor cell expression was associated with a better prognosis in all astrocytomas, and this was also seen in AAs. In contrast, FTL was not associated with survival, and for both FTH and FTL no difference was observed among malignancy grades. These results are different from
previous results obtained using TMAs composed of 95 grade II-IV gliomas of oligodendrogial and astroglial type, where high immunohistochemical scores for FTH and FTL were associated with shorter overall survival [20]. The discrepancy could be explained by inclusion of grade II and III oligodendrogial tumors in the TMA cohort, which is in contrast to our cohort containing only astrocytic tumors thereby reducing the risk of bias in the survival analysis. Focusing on GBMs and analyzing gene expression data from the TCGA dataset, high levels of FTH1 mRNA and FTL mRNA were previously found to be associated with poor outcome [20]. However, apparently these findings do not extend to the protein level as no association with survival was found in our data or in the TMA study [20]. In breast cancer, both high levels of FTH and FTL have been suggested to be associated with poor outcome [35]. However, in triple-negative breast cancer, high FTH expression was a favorable prognostic factor if the protein was present in the cytoplasm [36], thereby adding to the complexity of understanding and using iron-related proteins as biomarkers. In the context of gliomas, the four different molecular GBM subtypes may influence survival analysis in GBMs, especially when working with smaller patient cohorts [37]. To elucidate whether the expression levels of TfR1, FTH, and FTL differed among the GBM subtypes, we used the TCGA dataset and found that neural and especially mesenchymal GBMs overall had the highest expression levels of the three iron-related genes. When investigating the association between the three iron-related genes and overall survival in the four different GBM subtypes, high mRNA levels of TfR1 significantly correlated with overall survival, but only in the mesenchymal and proneural subtypes. Thus, accounting
for GBM subtype in the survival analysis performed on our patient cohort could increase the prognostic significance of the three iron-related proteins, especially TfR1, although a larger cohort would be needed to ensure statistical significance.

More recently, a study from Wu et al. showed that FTL was elevated in GBM and silencing FTL in vitro inhibited the cell proliferation [38]. Gautam et al. found that the plasma levels of FTL were higher in GBM patients compared to healthy controls; however, this could also reflect that FTL is a marker for inflammation [39]. Altogether, these studies suggest that FTL plays a role in glioma biology, but the precise role of FTL needs to be further investigated.

FTH and FTL were expressed by a few CD133-positive cells suggesting that ferritins may not play a crucial role in the BTIC phenotype. However, in a recent study ferritins were found to be co-expressed to some extent with SOX2 [20]. In contrast, we did not observe any co-expression between the ferritins and nestin. This could be due the hierarchy that exists within the BTIC population as nestin may be expressed primarily by cells committed to the neural lineage, while CD133 and especially SOX2 may be expressed by more immature cells [40]. However, this possible relation between BTIC and iron-related proteins needs further investigation.

Interestingly, we also found co-expression between ferritins and IBA-1, a specific marker of microglia and macrophages suggesting an important role of microglia/macrophages in brain tumor iron homeostasis which has also been reported by other groups [41–43]. Reportedly, microglia/macrophages are more prevalent in the mesenchymal subtype of GBM [44] suggesting that the microglial/macrophage contribution to the iron homeostasis is most significant in this GBM subtype. In return, iron status was found to influence microglial release of pro-inflammatory cytokines [45]. We approached the potential microglial contribution to glioma survival by scoring cells with a morphology resembling microglia/macrophages...
in the two immunohistochemical ferritin stainings. We observed that a high microglial score in the FTL staining was associated with poor prognosis in all grades combined as well as in AAs. In contrast, low FTH microglial score was associated with poor outcome in AAs. This observation could be explained by microglial phenotype e.g. polarization of microglia towards a pro-inflammatory or an anti-inflammatory phenotype thereby potentially influencing survival. Accordingly, iron-related proteins may play different roles in different cell types highlighting the complexity of interpreting expression of iron-related proteins and using these proteins as biomarkers.

Using iron-related proteins as targets may also be challenging. Several drugs targeting TfRs have been developed and tested in different cancers. In gliomas, phase I and II clinical trials with the TfR ligand transferrin conjugated to diphtheria toxin have been conducted on patients with recurrent GBMs showing promising results [46, 47]. However, in a phase III trial the drug failed mainly due to CNS toxicity [48, 49]. Systematic interrogation of iron flux recently showed that tumor stem cells require TfR1 and ferritins to propagate and form tumors in vivo [20] supporting that strategies compromising iron flux could be successful since the aspect of the tumor stem cells is taken into account. Using whole slides of non-cultured patient tumor tissue, our results supported this showing that TfR1, FTH, and FTL were co-expressed to some extent with the stem cell marker CD133, and we furthermore found that TfR1 was elevated in GBMs and associated with short survival in astrocytomas. On the other hand, the results obtained from survival analyses with FTH and FTL and the identified microglial expression suggest that iron-flux in gliomas may be dependent of different cell types and cross-talk between these cell types.

In conclusion, we found that TfR1 tumor cell expression increased with malignancy grade. No grade-dependent increase was found for the tumor cell expression of FTH and FTL, but the expression level of FTL by microglia was highest in GBMs. These findings suggest that iron-related proteins, primarily TfR1 and ferritins, may be associated with tumor aggressiveness. The prognostic values of TfR1, FTH, and FTL in the individual astrocytoma grades were limited. However, high microglial/macrophage expression of FTL, but not FTH, correlated with shorter survival in all astrocytomas suggesting that development of future therapeutic strategies compromising iron flux should take tumors cells as well as microglia/macrophages into account.

Supporting information

S1 Fig. Association between iron-related mRNA levels and overall survival in the different GBM subtypes. In the classical GBM subtype, no significant association between overall survival and TfR1 (A), FTH (B), or FTL (C) was found. In the mesenchymal subtype, high levels of TfR1 correlated with poor prognosis (D), while no significant correlation was found between overall survival and FTH (E) or FTL (F). In neural GBMs, TfR1 (G), FTH (H), and FTL (I) did not correlate with survival. In proneural GBMs, high TfR1 was significantly associated with shorter overall survival (J). Similar tendency was observed for FTH (K), while no correlation existed between overall survival and FTL mRNA levels (L).

Abbreviations: FTH ferritin heavy chain, FTL ferritin light chain, GBM glioblastoma, TfR1 transferrin receptor-1.

(TIF)

S1 File. Clinicopathological data on the patients investigated in the current study.

(XLSX)

S2 File. Datasets generated from the Cancer Genome Atlas (TCGA).

(XLSX)
Acknowledgments

We acknowledge the excellent laboratory work by the technicians Helle Wohlleben and Tanja Dreehsen Høgaard. This work was supported by the Odense University Hospital Research Funds, University of Southern Denmark, Agnete Lövgren’s legat, Familien Hede Nielsen’s Foundation, Meta and Håkon Bagger’s Foundation, and Else and Mogens Wendell-Wedelborg Foundation.

Author Contributions

Conceptualization: Ann Mari Rosager, Rikke H. Dahlrot, David L. Schonberg, Jeremy N. Rich, Justin D. Lathia, Bjarne W. Kristensen.

Data curation: Ann Mari Rosager, Mia D. Sørensen, Rikke H. Dahlrot, Bjarne W. Kristensen.

Formal analysis: Ann Mari Rosager, Mia D. Sørensen, Bjarne W. Kristensen.

Funding acquisition: Bjarne W. Kristensen.

Investigation: Ann Mari Rosager, Mia D. Sørensen, Rikke H. Dahlrot, Bjarne W. Kristensen.

Methodology: Ann Mari Rosager, Mia D. Sørensen, Rikke H. Dahlrot, Steinbjørn Hansen, Bjarne W. Kristensen.

Project administration: Bjarne W. Kristensen.

Resources: Bjarne W. Kristensen.

Software: Ann Mari Rosager, Mia D. Sørensen, Rikke H. Dahlrot, Bjarne W. Kristensen.

Supervision: Mia D. Sørensen, Rikke H. Dahlrot, Bjarne W. Kristensen.

Validation: Ann Mari Rosager, Mia D. Sørensen, Bjarne W. Kristensen.

Visualization: Ann Mari Rosager, Mia D. Sørensen.

Writing – original draft: Ann Mari Rosager, Mia D. Sørensen.

Writing – review & editing: Mia D. Sørensen, Rikke H. Dahlrot, Steinbjørn Hansen, David L. Schonberg, Jeremy N. Rich, Justin D. Lathia, Bjarne W. Kristensen.

References

1. Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine. 2008; 359 (5):492–507. Epub 2008/08/02. https://doi.org/10.1056/NEJMra0708126 PMID: 18669428.

2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352 (10):987–96. Epub 2005/03/11. https://doi.org/10.1056/NEJMoa043330 PMID: 15758009.

3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCICTrial. The lancet oncology. 2009; 10(5):459–66. https://doi.org/10.1016/S1470-2045(09)70025-7 PMID: 19269895.

4. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011; 146(1):53–66. Epub 2011/07/07. https://doi.org/10.1016/j.cell.2011.06.006 PMID: 21729780; PubMed Central PMCID: PMCPMC3144745.

5. Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Molecular aspects of medicine. 2013. Epub 2013/07/09. https://doi.org/10.1016/j.mam.2013.06.004 PMID: 23831316; PubMed Central PMCID: PMCPMC3866208.

6. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011; 18(5):829–40. https://doi.org/10.1038/cdd.2010.150 PMID: 21127501; PubMed Central PMCID: PMC3095828.
Iron-related proteins in astrocytomas

7. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. Journal of neuro-oncology. 2011; 103(1):43–58. Epub 2010/09/14. https://doi.org/10.1007/s11060-010-0357-8 PMID: 20835751.

8. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell. 2009; 15(6):501–13. Epub 2009/05/30. https://doi.org/10.1016/j.ccr.2009.03.018 PMID: 19477429; PubMed Central PMCID: PMCPMC2693960.

9. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature neuroscience. 2013; 16(10):1373–82. Epub 2013/09/03. https://doi.org/10.1038/nn.3510 PMID: 23995067; PubMed Central PMCID: PMCPMC3930177.

10. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta 1 signaling pathway. Journal of Immunology (Baltimore, Md: 1950). 2012; 189(1):444–53. Epub 2012/06/06. https://doi.org/10.4049/jimmunol.1103248 PMID: 22864874.

11. Huang J, Simcox J, Mitchell TC, Jones D, Cox J, Luo B, et al. Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice. FASEB J. 2013; 27(7):2845–54. https://doi.org/10.1096/fj.12-216929 PMID: 23515442; PubMed Central PMCID: PMC3688748.

12. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). The Journal of clinical investigation. 2007; 117(7):1926–32. https://doi.org/10.1172/JCI3495 PMID: 17557118; PubMed Central PMCID: PMCPMC1884690.

13. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nature reviews Cancer. 2013; 13(5):342–55.

14. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular disease. Seminars in pediatric neurology. 2006; 13(3):142–8.

15. Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother. 2001; 55(6):333–9. PMID: 11478586.

16. Rouault TA, Cooperman S. Brain iron metabolism. Seminars in pediatric neurology. 2006; 13(3):142–8. https://doi.org/10.1016/j.spen.2006.08.002 PMID: 17101452.

17. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Pinchet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006; 121(2):144–58. https://doi.org/10.1016/j.clim.2006.06.010 PMID: 16904380.

18. Connor JR, Menzies SL, Burdo JR, Boyer PJ. Iron and iron management proteins in neurobiology. Pediatric neurology. 2001; 25(2):118–29. PMID: 11551742.

19. Liu HD, Li W, Chen ZR, Zhou ML, Zhuang Z, Zhang DD, et al. Increased expression of ferritin in cerebral cortex after human traumatic brain injury. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013; 34(7):1173–80. https://doi.org/10.1007/s10072-012-1214-7 PMID: 23079850.

20. Schoner DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer cell. 2015; 28(4):441–55. Epub 2015/10/16. https://doi.org/10.1016/j.ccell.2015.09.002 PMID: 26461092; PubMed Central PMCID: PMCPMC4646058.

21. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II–IV astrocytomas. Journal of neuro-oncology. 2008; 90(2):157–70. Epub 2008/07/10. https://doi.org/10.1007/s11060-008-9648-8 PMID: 18612800.

22. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 423(7015):396–401. Epub 2004/11/19. https://doi.org/10.1038/nature01326 PMID: 15354017.

23. Corti S, Nizzardo M, Nardini M, Donadoni C, Locatelli F, Papadimitriou D, et al. Isolation and characterization of murine neural stem/progenitor cells based on Prominin-1 expression. Experimental neurology. 2007; 205(2):547–62. https://doi.org/10.1016/j.expneurol.2007.03.021 PMID: 17466977.

24. Dahilot RH, Hansen S, Jensen SS, Schroder HD, Hjelmborg J, Kristensen BW. Clinical value of CD133 and nestin in patients with glioma: a population-based study. International journal of clinical and experimental pathology. 2014; 7(7):3739–51. Epub 2014/08/15. PMID: 25120750; PubMed Central PMCID: PMCPMC4128985.

25. Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J, Nakazato Y. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol. 2012; 29(3):160–7. https://doi.org/10.1007/s10014-012-0081-5 PMID: 22350668.
26. Kim JS, Kim J, Kim Y, Yang M, Jang H, Kang S, et al. Differential patterns of nestin and glial fibrillary acidic protein expression in mouse hippocampus during postnatal development. J Vet Sci. 2011; 12 (1):1–6. https://doi.org/10.4142/jvs.2011.12.1.1 PMID: 21368556; PubMed Central PMCID: PMC3053460.

27. Louis DN, International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007. 309 p.

28. Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, et al. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of neurology. 2012; 72(5):766–78. Epub 2013/01/03. https://doi.org/10.1002/ana.23674 PMID: 23280793; PubMed Central PMCID: PMC3615417.

29. Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule as a a cancer stem cell maintenance factor. Cell reports. 2014; 6(1):117–29. Epub 2014/01/01. https://doi.org/10.1016/j.celrep.2013.11.043 PMID: 24373972; PubMed Central PMCID: PMC3899718.

30. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061–8. Epub 2008/09/09. https://doi.org/10.1038/nature07385 PMID: 18772890; PubMed Central PMCID: PMCPM2671642.

31. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer. 1981; 27(3):329–34. PMID: 6270015.

32. Panaccio M, Zalcberg JR, Thompson CH, Leyden MJ, Sullivan JR, Lichtenstein M, et al. Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo. Immuno Cell Biol. 1987; 65 (Pt 1):461–72. https://doi.org/10.1038/icb.1987.55 PMID: 2452131.

33. Prutki M, Poljak-Blaži M, Jakopović M, Tomas D, Stipančić I, Zarković N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer letters. 2006; 238(2):188–96. https://doi.org/10.1010/j.canlet.2005.07.001 PMID: 16111806.

34. Kondo K, Noguchi M, Mukai K, Matsuno Y, Sato Y, Shimosato Y, et al. Transferin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest. 1990; 97(6):1367–71. PMID: 2186965.

35. Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog. 2013; 18(5):435–49. PMID: 23879588; PubMed Central PMCID: PMC3736347.

36. Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trampan-Jansen AM, Foekens R, et al. Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response. Mol Cell Proteomics. 2014; 13(7):1814–27. https://doi.org/10.1074/mcp.M113.037176 PMID: 24742827; PubMed Central PMCID: PMC4083117.

37. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17(1):98–110. Epub 2010/02/05. https://doi.org/10.1016/j.ccr.2009.12.020 PMID: 20129251; PubMed Central PMCID: PMCPM2818769.

38. Wu T, Li Y, Liu B, Zhang S, Wu L, Zhu X, et al. Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway. PloS one. 2016; 11(2):e0149361. Epub 2016/02/13. https://doi.org/10.1371/journal.pone.0149361 PMID: 26871431; PubMed Central PMCID: PMC4752301.

39. Gautam P, Nair SC, Gupta MK, Sharma R, Poliesetty RV, Uppin MS, et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by Traq-based quantitative proteomic analysis. PloS one. 2012; 7(9):e46153. Epub 2012/10/03. https://doi.org/10.1371/journal.pone.0046153 PMID: 23029420; PubMed Central PMCID: PMC3461020.

40. Bradshaw A, Wickremesekera A, Tan ST, Peng L, Davis PF, Tinteneāng T. Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Frontiers in surgery. 2016; 3:21. Epub 2016/05/06. https://doi.org/10.3389/fsurg.2016.00021 PMID: 27148537; PubMed Central PMCID: PMCPMC4831983.

41. Kaneko Y, Kitamoto T, Tateishi J, Yamaguchi K. Ferritin immunohistochemistry as a marker for microglia. Acta neuropathologica. 1989; 79(2):129–36. Epub 1989/01/01. PMID: 2596262.

42. Connor JR, Menzies SL, St Martin SM, Mufson EJ. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. Journal of neuroscience research. 1990; 27(4):595–611. https://doi.org/10.1002/jnr.490270421 PMID: 2079720.

43. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. Journal of neuroscience research. 1992; 31(1):75–8. https://doi.org/10.1002/jnr.490310111 PMID: 1613823.

44. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-κappaB promotes radiation resistance in glioblastoma. Cancer
45. Zhang X, Surguladze N, Slagle-Webb B, Cozzi A, Connor JR. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia. 2006; 54(8):795–804. Epub 2006/09/08. https://doi.org/10.1002/glia.20416 PMID: 16958088.

46. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (TI-CRM107) for therapy of malignant gliomas. Journal of neuro-oncology. 2003; 65(1):3–13. PMID: 14649881.

47. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature medicine. 1997; 3(12):1362–8. PMID: 9396606.

48. Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. The Journal of membrane biology. 2014; 247(4):291–307. Epub 2014/02/28. https://doi.org/10.1007/s00232-014-9637-0 PMID: 24573305.

49. Debinski W. Molecular Targeting With Recombinant Cytotoxins for the Treatment of Brain Tumors. Drug Develop Res. 2008; 69(7):407–14. https://doi.org/10.1002/ddr.20272